Feature / NICE update

NICE published the following guidance in October:

Clinical guidelines

• CG152 Crohn's disease: management in adults, children and young people – A costing statement has been produced rather than a costing report and template for this guideline because it is considered that implementing the recommendations will not have a significant national resource impact.
• CG153 Psoriasis: the assessment and management of psoriasis – Because of the variation in current practice, the national cost impact of implementing the guidance is uncertain. However, examples of potential cost impacts are included. It is suggested that the changes in topical prescribing sequence, and use of a second biologic could lead to cost increases of around £15,000, and £730 respectively per 100,000 people. However, it should be noted that these estimates are heavily dependent on broad estimates of current practice.

Technology guidance

• TA265 Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours – The annual incremental treatment costs associated with implementing this recommendation are estimated as £46m for the population of England, based on the standard assumptions in the model and the list price of denosumab. The manufacturer of denosumab has agreed a patient access scheme with the Department of Health, in which a discount on the list price of denosumab is offered. The size of the discount is commercial-in-confidence.

Public health guidance

• PH40 Social and emotional wellbeing: early years – A costing statement has been produced rather than a costing report and template for this guidance as it is considered implementing the recommendations will not have a significant national resource impact. The costing statement indicates that investing in prevention, education and early intervention services for 0 to 5-year-olds could lead to a big reduction in public service costs in the longer term, including the costs to healthcare, social services and the police and criminal justice system. NICE update was prepared by Stephen Brookfield, senior costing analyst at NICE